ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 3, Pages 687
Publisher
MDPI AG
Online
2020-03-19
DOI
10.3390/cancers12030687
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer
- (2020) Natalie Yan Li Ngoi et al. Cancers
- Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer
- (2020) Joseph Sia et al. Frontiers in Cell and Developmental Biology
- Targeting apoptotic caspases in cancer
- (2020) Ashley Boice et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
- (2019) Gabriel Balmus et al. Nature Communications
- Structural basis of allosteric regulation of Tel1/ATM kinase
- (2019) Jiyu Xin et al. CELL RESEARCH
- Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
- (2019) Lin Mei et al. Journal of Hematology & Oncology
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining and Modulating ‘BRCAness’
- (2019) Andrea K. Byrum et al. TRENDS IN CELL BIOLOGY
- Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
- (2019) Nicholas R. Jette et al. BRITISH JOURNAL OF CANCER
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Near-Complete Structure and Model of Tel1ATM from Chaetomium thermophilum Reveals a Robust Autoinhibited ATP State
- (2019) Marijke Jansma et al. STRUCTURE
- Cryo-EM Structure of Nucleotide-Bound Tel1ATM Unravels the Molecular Basis of Inhibition and Structural Rationale for Disease-Associated Mutations
- (2019) Luke A. Yates et al. STRUCTURE
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
- (2018) Dalia Kamel et al. CURRENT DRUG TARGETS
- Homologous recombination and the repair of DNA double-strand breaks
- (2018) William Douglass Wright et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- High speed of fork progression induces DNA replication stress and genomic instability
- (2018) Apolinar Maya-Mendoza et al. NATURE
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Repair in Prostate Cancer: Biology and Clinical Implications
- (2017) Joaquin Mateo et al. EUROPEAN UROLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
- (2017) Ahrum Min et al. MOLECULAR CANCER THERAPEUTICS
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
- (2017) Chen Wang et al. Translational Oncology
- Accelerating Discovery of Functional Mutant Alleles in Cancer
- (2017) Matthew T. Chang et al. Cancer Discovery
- Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness
- (2017) Qiuji Wu et al. Frontiers in Immunology
- A new role for ATM in selective autophagy of peroxisomes (pexophagy)
- (2016) Durga Nand Tripathi et al. Autophagy
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and thep53status
- (2016) Shazie Yusein-Myashkova et al. JOURNAL OF BIOCHEMISTRY
- ATM Mutations in Cancer: Therapeutic Implications
- (2016) M. Choi et al. MOLECULAR CANCER THERAPEUTICS
- Ataxia telangiectasia: a review
- (2016) Cynthia Rothblum-Oviatt et al. Orphanet Journal of Rare Diseases
- ATM protein is deficient in over 40% of lung adenocarcinomas
- (2016) Liza C. Villaruz et al. Oncotarget
- The interplay between DNA repair and autophagy in cancer therapy
- (2015) Dan Zhang et al. CANCER BIOLOGY & THERAPY
- The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle
- (2015) I. A. Shaltiel et al. JOURNAL OF CELL SCIENCE
- Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- (2015) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
- (2015) Matthew T Chang et al. NATURE BIOTECHNOLOGY
- ATM functions at the peroxisome to induce pexophagy in response to ROS
- (2015) Jiangwei Zhang et al. NATURE CELL BIOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
- (2015) Frank P. Vendetti et al. Oncotarget
- A Systematic Analysis of Factors Localized to Damaged Chromatin Reveals PARP-Dependent Recruitment of Transcription Factors
- (2015) Lior Izhar et al. Cell Reports
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis
- (2014) H. Kim et al. CLINICAL CANCER RESEARCH
- ATM: Expanding roles as a chief guardian of genome stability
- (2014) Yosef Shiloh EXPERIMENTAL CELL RESEARCH
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
- (2012) William H. Chappell et al. CELL CYCLE
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
- (2012) Chris T. Williamson et al. EMBO Molecular Medicine
- The Heterochromatic Barrier to DNA Double Strand Break Repair: How to Get the Entry Visa
- (2012) Aaron A. Goodarzi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
- (2011) Jean-Damien Charrier et al. JOURNAL OF MEDICINAL CHEMISTRY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- The ATM protein kinase and cellular redox signaling: beyond the DNA damage response
- (2011) Scott Ditch et al. TRENDS IN BIOCHEMICAL SCIENCES
- ATM Mutations in Patients with Hereditary Pancreatic Cancer
- (2011) Nicholas J. Roberts et al. Cancer Discovery
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Site-specific Phosphorylation Dynamics of the Nuclear Proteome during the DNA Damage Response
- (2010) Martin V. Bennetzen et al. MOLECULAR & CELLULAR PROTEOMICS
- ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
- (2010) C. T. Williamson et al. MOLECULAR CANCER THERAPEUTICS
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
- The combined status of ATM and p53 link tumor development with therapeutic response
- (2009) H. Jiang et al. GENES & DEVELOPMENT
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
- (2008) Christopher J. Lord et al. DNA REPAIR
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started